Skip to main content
. 2024 Mar 11;16(1):2321635. doi: 10.1080/19420862.2024.2321635

Figure 2.

Figure 2.

Schematic representation, indication and mechanism of action of approved bsAbs: a) T cell engagers (TCE), b) factor VIII mimetic, dual signaling inhibition: c) bispecific receptor tyrosine kinase (RTK) inhibitor (BsRtki), d) bispecific checkpoint inhibitor (BsCPI), e) dual ligand inhibitor (DLI), f) half-life extended (HLE) ligand inhibitor. Created with Biorender.com.